CP (CP) is a movement disorder caused by an upper motor neuron (UMN) lesion in the
developing brain
[1]. There are a range of prenatal, perinatal, and postnatal
causes of CP and it is often associated with periventricular leukomalacia
[2]. CP covers a
spectrum of severities and is the most common childhood movement disorder with a
prevalence of 3.6 cases per 1000 in the US that has not decreased with medical
advances
[3]. While the UMN lesion that initiates CP is
non-progressive, many secondary changes occur within the musculoskeletal system that
are progressive and debilitating
[4]. Among the hallmarks of CP
is muscle spasticity, in which the muscle contracts in a velocity dependent
resistance to stretch that results, in part, from reduced inhibition of the stretch
reflex
[5]. While
the disability that results from spasticity is variable
[6],
[7] patients with spastic CP may also
develop muscle contractures secondary to the lesion. Fixed muscle contractures
represent a unique muscle adaptation in which muscles detrimentally limit the range
of motion around a joint without being activated. These muscle contractures limit
mobility, may be painful, and represent a major disability among those affected by
CP or anyone with an UMN lesion
[8].
There are a variety of treatments designed to inhibit muscle activity in CP and
prevent contracture formation. Physical therapy techniques, oral muscle relaxants,
intrathecal placement of medication (baclofen), chemical neurectomies with phenol or
alcohol, chemodenervation using neurotoxins, and surgical neurectomies have all been
employed to decrease spasticity in children with CP
[9]. However, despite best clinical
practices, contractures still develop and often require surgery to correct
[10]. It should also
be noted that all of these therapies reduce muscle strength in a condition in which
strength is already compromised. Clearly current therapies are not ideal.
There are no known genetic defects in patients with CP and their muscles, as it is a
direct consequence of the UMN lesion
[11]. Although skeletal muscle is
known to be highly adaptive in response to neurological input, muscle contractures
that develop are part of an adaptive mechanism that is not fully understood.
Contracture does not develop in animal models of increased muscle use, which could
be present from decreased motor neuron inhibition, or even decreased muscle use,
which could result in decreased functionality
[4]. Indeed UMN contractures are
not readily reproducible in animal models, thus necessitating research on human
subjects
[12]. The
underlying transcriptional alterations have important consequences in the
development of increased passive mechanical properties and pathologic contracture.
Understanding the precise nature of transcripts differential regulation can
delineate the mechanisms that accompany contracture, including but not limited to
increased passive tension.
Previous research demonstrated that muscle stiffness in contracture is independent of
active muscle contraction
[13],
[14]. Recent mechanical measurements of biopsies from
pediatric hamstring muscles indicate that the increased muscle stiffness is due to
alterations in extracellular matrix (ECM) rather than the stiffness of muscle fibers
themselves
[15].
Multiple studies have also shown an increase in sarcomere length of muscle in
contracture, demonstrating contractured muscle experiences high intrinsic strain
[16] due to
dramatic, but unknown structural alterations. These results suggests a decrease in
the serial sarcomere number despite conflicting evidence as to whether muscle
fascicle length decreases
[17]–
[20]. Studies have shown that muscle and muscle fiber cross
sectional area are reduced, which decreases force production, and even that the
remaining muscle has decreased force generating capacity
[21]–
[23]. These mechanical and
architectural changes in muscle implicate a disruption of the biological components
involved in myogenesis, force generation, force transmission, extracellular matrix
maintenance, and perhaps additional pathways. Recent microarray data from the upper
extremity supports the assertion that CP muscle is altered transcriptionally and
that in addition to the pathways listed above, neuromuscular junction activity,
excitation-contraction coupling, and energy metabolism are also deranged
[24].
As a purely adaptive muscle disorder, contractures are believed to have an altered
transcriptional profile. The current study has taken advantage of a large surgical
population of both children with CP and typically developing children to conduct a
robust microarray analysis correlated to mechanical parameters. Our previous study
was limited by a very small control subject population which was not age matched,
(N

=

2)
[24], and microarray studies in humans subjects generally
require larger sample sizes to identify differences due to the higher variability
present in human tissues compared to most inbred animal strains. Additionally the
same biopsies reported here have been used to collect mechanical data that was
recently published, allowing the comparison of our transcriptional data to
functional parameters
[15]. We also took advantage of recent additions of muscle
specific gene ontologies and muscle specific gene networks to probe the muscle and
compare the pathology to microarrays from other published muscle conditions (
[25]; Smith et al.
in press). A mechanistic understanding of muscle adaptation to contracture may lead
to discovery of possible therapeutic targets that can delay or even reverse the
debilitating effects of CP or other UMN lesions.